Medtronic reports strong fiscal first-quarter results driven by cardiovascular growth, plans a spin-off of its diabetes division, and invests heavily in innovative surgical technologies, signalling a significant strategic restructuring amidst market uncertainties.
Jim Cramer used his September 8 “Mad Money” segment to frame Medtronic as an awkward but intriguing case: a healthcare group that has just delivered a stronger quarter, lifted guidance and still trades near the level it reached after reporting. He said the company’s improved performance sits uneasily beside its diabetes unit, which he described as a business he would not want to own as GLP-1 drugs reshape the market. Medtronic, for its part, has been trying to rework its portfolio around faster-growing areas while preparing to separate that division.
The company’s fiscal first-quarter results help explain the enthusiasm. Medtronic reported revenue of nearly $9.8 billion, with organic growth of 13.7% and adjusted diluted earnings per share of $1.45, according to its earnings call transcript. It raised its full-year organic revenue growth outlook to 7.25% to 7.75%, from 6.75% to 7.25%, and nudged up the bottom end of its non-GAAP EPS guidance to $5.94. Cardiovascular sales were the standout, rising 18.9% organically to $3.927 billion, while neuroscience increased 9.3% and medical surgical 10.2%.
There is, however, an important caveat in the quarter’s headline growth rate. Medtronic said the period included an extra fiscal week, which it estimated added about $570 million to organic growth. Even so, the company is pressing ahead with strategic investments that could reshape its device portfolio. It has agreed to commit $700 million for distribution rights to Cornerstone Robotics’ Sentire surgical system in selected markets outside the United States, and it plans to invest up to $80 million in Pi-Cardia, with an option to buy the company for as much as $210 million.
The diabetes separation is the other major piece of the story. Medical Economics reported that Medtronic plans to spin off the division into a standalone, publicly traded company within about 18 months, using a mix of capital market transactions that would begin with an initial public offering and be followed by a split-off. The move reflects management’s desire to concentrate on higher-margin growth businesses and to give investors a clearer way to value the diabetes operation separately. Insider Monkey also noted that hedge fund ownership of Medtronic rose in the second quarter, while short interest remained low, suggesting that some institutional investors are leaning into the turnaround rather than betting against it.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
